Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-20-006358
Filing Date
2020-04-14
Accepted
2020-04-14 16:06:59
Documents
63
Period of Report
2019-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm 10-K 1781871
2 ex4-3.htm EX-4.3 20221
3 ex21.htm EX-21 2028
4 ex23-1.htm EX-23.1 4707
5 ex31-1.htm EX-31.1 16965
6 ex31-2.htm EX-31.2 17554
7 ex32.htm EX-32 8482
  Complete submission text file 0001493152-20-006358.txt   7054400

Data Files

Seq Description Document Type Size
8 XBRL INSTANCE FILE rspi-20191231.xml EX-101.INS 1108506
9 XBRL SCHEMA FILE rspi-20191231.xsd EX-101.SCH 90112
10 XBRL CALCULATION FILE rspi-20191231_cal.xml EX-101.CAL 51803
11 XBRL DEFINITION FILE rspi-20191231_def.xml EX-101.DEF 279795
12 XBRL LABEL FILE rspi-20191231_lab.xml EX-101.LAB 550222
13 XBRL PRESENTATION FILE rspi-20191231_pre.xml EX-101.PRE 366238
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

EIN.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-16467 | Film No.: 20791437
SIC: 2834 Pharmaceutical Preparations